Pfizer Czech Republic made a net profit of CZK 103 mil with revenues of CZK 3,586 mil in 2017, up by 39.7% and up by 10.6%, respectively, compared to the previous year. This translates into a net margin of 2.86%.
On the operating level, EBITDA reached CZK 156 mil, up 30.7% compared to the previous year. Over the last five years, the company's EBITDA has risen 18.7% a year on average.
The company generated cash, defined by a sum of net profit and depreciation, of CZK 127 mil or 3.54% of sales. When investments are excluded, free cash flow reached CZK 3.21 mil, or 0.089% of sales in 2017.
In the last five years, the company generated free cash flow of CZK 4.76 mil. That compares to a cumulative net profit of CZK 529 mil in the same period.
You can see all the company’s data at Pfizer Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
